If you have been reading about metabolic research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-21. Numbers and descriptions here follow the published literature rather than marketing material.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Colombia has free-trade zones (FTZ), such as Zona Franca del Pacifico, located in the Valle del Cauca, one of the most striking areas for foreign investment. The financial sector has grown favorably due to good liquidity in the economy, the growth of credit and the positive performance of the Colombian economy. The Colombian Stock Exchange through the Latin American Integrated Market (MILA) offers a regional market to trade equities. Colombia is now one of only three economies with a perfect score on the strength of legal rights index, according to the World Bank. Colombia is rich in natural resources, and it is heavily dependent on energy and mining exports. Colombia's main exports include mineral fuels, oils, distillation products, fruit and other agricultural products, sugars and sugar confectionery, food products, plastics, precious stones, metals, forest products, chemical goods, pharmaceuticals, vehicles, electronic products, electrical equipment, perfumery and cosmetics, machinery, manufactured articles, textile and fabrics, clothing and footwear, glass and glassware, furniture, prefabricated buildings, military products, home and office material, construction equipment, software, among others. Principal trading partners are the United States, China, the European Union and some Latin American countries. Non-traditional exports have boosted the growth of Colombian foreign sales as well as the diversification of destinations of export thanks to new free trade agreements.
==== Iturins ==== Iturins are pore‐forming lipopeptides with antifungal activity, and this is dependent on the interaction with the cytoplasmic membrane of the target cells. Mycosubtilin is an iturin isoform that can interact with membranes via its sterol alcohol group, to target ergosterol (a compound found in fungi) to give it antifungal properties.
kinase Any of a class of enzymes which catalyze the transfer of phosphate groups from high-energy, phosphate-donating molecules such as ATP to one or more specific substrates, a process known as phosphorylation. The opposite process, known as dephosphorylation, is catalyzed by phosphatase enzymes.
Sources: en.wikipedia.org
On 6 July 2011, another version of the discussion paper was circulated by the central government of India. Comments from a wide cross-section of Indian society including farmers' associations, industry bodies, consumer forums, academics, traders' associations, investors, economists were analysed in depth before the matter was discussed by the Committee of Secretaries. By early August 2011, the consensus from various segments of Indian society was overwhelming in favour of retail reforms. The reform outline was presented in India's Rajya Sabha in August 2011. The announced reforms are the result of this consensus process. The current opposition is not helping the consensus process, since consensus is not built by threats and disruption. Those who oppose current retail reforms should help build consensus with ideas and proposals. The opposition parties currently disrupting the Indian parliament on retail reforms have not offered even one idea or a single proposal on how India can eliminate food spoilage, reduce inflation, improve food security, feed the poor, improve the incomes of small farmers. A study by Global Insights research found that modern retailers such as Walmart create jobs directly, indirectly and by induced effects. In Dallas-Fort Worth area of the United States, with a population of about 2 million people, Global Insights found that Walmart alone had helped create about 6,300 new net jobs with an average salary of over $21,000 each.
== Production == Aerated chocolate containing large bubbles is produced via two methods. In the first, melted chocolate is put under a vacuum, where it foams up. As the chocolate cools, and the fats within the chocolate set, the foam structure remains. Sometimes gases such as carbon dioxide are introduced into the mixture before it is placed under the vacuum. Although the method easily permits inclusions such as nougat or nuts, the production is labor-intensive and difficult to keep hygienic. As a result, the second method is more frequently used: working gases into liquid, tempered chocolate under high pressure. Carbon dioxide is mainly used, although others include nitrous oxide. Air is avoided, as oxygen causes chocolate to become rancid. Any gases that do not dissolve are dispersed as bubbles through the chocolate using a beater. As the chocolate is released from the high pressure conditions, the bubbles expand, foaming the product; through this, the amount of pressure directly impacts bubble size. The setting chocolate is deposited in a moulded shell, after which the set interior is capped with liquid tempered chocolate. Factors that affect bubble size include qualities of chocolate, such as viscosity and the rate of setting. The ingredients used, such as emulsifiers and milk fats also impact bubble size; other factors include type of gas and how much pressure is applied. Micro-aerated chocolate is created using the method of beating gases in under high pressure.
Under its terms the newly created High Commission Territory of Basutoland was to be indirectly ruled by the Basutoland High Commissioner Marshal Clarke. The Basuto retained their guns, prevented the alienation of their land to white settlement and thwarted the absorption of their country by the Free State, which would have inevitably occurred had they gained complete independence. The Basuto chiefs retained most of their past authority, while unrest in Masopha's district was only brought to an end after his defeat in the 1898 Basuto Civil War. The Basuto Gun War represents a rare example of an African nation's military victory against a colonial power in the 19th century. Its status as a High Commission Territory meant that Basutoland was not incorporated into the Union of South Africa in 1910.
The hot water supply hose of the umbilical is commonly 1⁄2 inch (13 mm) bore, and is connected to a supply manifold at the right hip of the suit with a set of valves which allow the diver to control flow to the front and back of the torso, and to the arms and legs, and to dump the supply to the environment if the water is too hot or too cold. The manifold distributes the water through the suit through perforated tubes. The hot-water suit is normally a one-piece neoprene wetsuit, fairly loose fitting, to fit over a neoprene undersuit, which can protect the diver from scalding if the temperature control system fails, with a zipper on the front of the torso and on the lower part of each leg. Gloves and boots are worn which receive hot water from the ends of the arm and leg hoses. If a full-face mask is worn, the hood may be supplied by a tube at the neck of the suit. Helmets do not require heating. The heating water flows out at the neck and cuffs of the suit through the overlap with gloves, boots, or hood.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.